Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says

Executive Summary

Studying multiple indications 'not the right way to approach biosimilars,' agency says; Amgen conducted more studies than needed for its proposed Humira biosimilar to enhance patient and physician confidence.

Advertisement

Related Content

Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Celltrion's Biosimilar Clinical Evidence Heavily Weighted By Ex-US Data
EU Data Helps Sandoz’s U.S. Clinical Program For Filgrastim

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel